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Humans have been fighting Ebola virus disease (EVD) 
since its first outbreak in 1976 in Yambuku village in the 
Democratic Republic of the Congo (previously Zaire). EVD 
is part of the Filoviridae family of viruses that includes 
Ebola and Marburg viruses. To date, EVD, one of the most 
deadly communicable diseases known to humans, has had 
15 outbreaks in Africa. In 2014, the most severe and com-
plicated outbreak yet swept through the West African coun-
tries of Guinea, Liberia, Nigeria, Senegal and Sierra Leone, 
with an initial case fatality rate of 70.8% [1]. As of 23 Sep-
tember 2014, with the situation seemingly still out of con-
trol, the number of suspected and confirmed cases was 
6,553, with 3,083 deaths, including 208 healthcare workers. 
The mechanisms by which EVD causes multisystem dis-
ease are poorly understood, and unfortunately, there are 
currently no licensed vaccines or drugs available for the 
treatment of EVD. Present treatment strategies for EVD are 
mainly supportive, while potentially effective vaccines and 
drugs (e.g., ZMapp) are still in varying stages of develop-
ment. EVD is characterized by immune suppression and 
systemic inflammatory response syndrome (SIRS) that 
causes impairment of the vascular, coagulation, and im-
mune systems, leading to shock and multiorgan failure. 
Some characteristics of SIRS pathophysiology resemble 
septic shock. In patients with septic shock, replacement 
doses of corticosteroids are thought to improve the mortality 
rate and reduce the duration of symptoms. Therefore, could 
a similar existing effect occur in those within EVD? Taking 
into account the role of significant inflammatory responses 
in EVD pathogenesis, we hypothesized that EVD patients 
might derive benefit from corticosteroid treatment to im-
prove their clinical outcomes. 
Monocytes, macrophages and immature dendritic cells, 
which are the initial sites for Ebola virus infection and rep-
lication, play a key role in the inflammatory processes dur-
ing EVD. Infection of these cells leads to the uncontrolled 
release of pro-inflammatory cytokines and chemokines, 
including tumor necrosis factor-α (TNF-α), interferon (IFN), 
interleukin (IL)-2, IL-1β, IL-10 and macrophage inflamma-
tory protein 1α (MIP-1α), as well as reactive oxygen and 
nitrogen radicals. These mediators attract increasing num-
bers of monocytes and macrophages as well as neutrophils, 
which release mediators of vasodilation and increase vascu-
lar permeability [2]. In particular, elevated levels of TNF-α 
followed by an increase in endothelial permeability might 
play an important role in the induction of circulatory shock 
during filovirus infection.  
Failure of the early activation of T cells and the subse-
quent compromised adaptive immunity in EVD, including 
antibody and cytokine responses, is followed by the exten-
sive apoptosis of blood leukocytes, and is closely associated 
with the fatal outcome of the disease. In the 2000 EVD out-
break in Uganda, a decrease in the number of circulating T 
lymphocytes was noted in people with fatal disease whereas 
cell counts were not reduced significantly in patients who 
survived the disease [3]. Impaired dendritic cell function 
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caused by EVD may contribute to lymphocyte apoptosis. 
Furthermore, high levels of TNF-α produced by infected 
monocytes and macrophages also have an important role in 
lymphocyte apoptosis induced by TNF-related apopto-
sis-inducing ligand (TRAIL). 
Elevated cytokine levels have been detected in the serum 
of patients with active EVD. Serum levels of pro-inflam- 
matory cytokines in non-survivors were between five and 
1000 times greater than that of convalescent or healthy in-
dividuals at the time of death [4]. Damage caused either 
directly by viral replication, or by the detrimental up-   
regulation of pro-inflammatory cytokines, exacerbates the 
symptoms of disease and provides the platform for shock, 
multiorgan failure and death. Recovery from EVD requires 
an early, transient and controlled inflammatory response, 
which helps control virus replication and spread while sim-
ultaneously initiating the adaptive immune response. 
An intact hypothalamic-pituitary-adrenal axis with effec-
tive intracellular glucocorticoid anti-inflammatory activity 
is essential for host survival following exposure to an infec-
tious agent. Cortisol levels were reported to be elevated in 
patients in EVD. Viral infection can increase glucocorticoid 
concentrations during an acute infection to suppress 
pro-inflammatory responses that otherwise might be fatal. 
Cortisol levels ranged from 555 to 1110 nmol L1 in 
asymptomatic patients with Ebola infection compared with 
133–377 nmol L1 in endemic control subjects [5]. 
However, adrenocortical infection and necrosis were also 
reported in humans and non-human primates infected with 
Ebola virus [6]. Inadequate intracellular glucocorticoid ac-
tivity, referred to as critical illness-related corticosteroid 
insufficiency, typically results in an exaggerated pro- 
inflammatory response. Impaired steroid secretion leads to 
hypotension and sodium loss with hypovolemia, both of 
which have been reported in nearly all cases of EVD. Im-
pairment of adrenocortical function by Ebola virus infection 
could therefore have an especially important role in the 
evolution of shock that typifies the late stages of EVD. 
The anti-inflammatory actions of corticosteroids have 
been known since the 1940s. Because of their potent anti- 
inflammatory and diverse immuno-modulatory activities, 
corticosteroids have been widely used to treat many 
inflammatory and autoimmune diseases. Although there are 
controversies regarding their use, adjunctive corticosteroid 
treatment has preferential benefit in cases of severe infec-
tion where exaggerated inflammatory responses mediate the 
pathophysiology of disease (e.g., septic shock, severe 
pneumonia, avian influenza, and severe acute respiratory 
syndrome coronavirus). However, to our knowledge, no 
clinical studies have reported the efficacy of corticosteroids 
against EVD. Previous reports have focused on the treat-
ment efficacy of corticosteroids against other types of viral 
hemorrhagic fever (VHF), such as Crimean-Congo hemor-
rhagic fever (CCHF), dengue hemorrhagic fever (DHF) and 
Hantaviruses hemorrhagic fever. In patients with CCHF and 
severe thrombocytopenia, high-dose methylprednisolone 
(10–30 mg kg1 per day) reduced fever, increased platelet 
and leukocyte counts, decreased internal bleeding and de-
creased dependency on blood products and reduced the 
mortality rate [7]. Despite the lack of clear survival benefit 
in patients with severe DHF, corticosteroids might help in 
reducing symptoms, improve well-being, shorten the time to 
platelet recovery or shorten the length of hospital stays [8].  
Although different pathogens, such as EVD, CCHF, and 
DHF, have similar clinical features, such as fever, throm-
bocytopenia, hemorrhage, shock and multiple organ failure, 
treatment options for them are limited and are based on 
general supportive management. Similar to EVD, the path-
ogenesis of CCHF might be the result of direct injury of 
virus-infected tissues followed by the indirect effects of host 
immune responses, with abnormally high levels of cyto-
kines and chemokines produced by activated monocytes and 
macrophages [9]. Early and well regulated inflammatory 
responses were associated with recovery from EVD. Alt-
hough some DHF studies suggested that corticosteroids 
were not effective in reducing mortality and serious com-
plications [10], it is important to consider the use of any 
potential effective treatment modalities because of the high 
mortality rate of EVD. Considering the past experiences 
with other VHFs, as well as inflammatory responses and 
impaired adrenocortical function in EVD, corticosteroids 
may be one of the better current options for treating patients 
with EVD.  
Corticosteroids can be useful for treating infectious dis-
eases when inflammation is particularly severe, but can be 
dangerous when the activation of inflammatory processes 
remains within the normal range. An important question is 
not just whether corticosteroid treatment will improve out-
comes in various aspects of morbidity and mortality caused 
by EVD, but also whether it is safe. In addition to the in-
creased risk of opportunistic infections and gastrointestinal 
bleeding caused by corticosteroids, enhancement of the 
current disease because of suppressed innate antiviral 
mechanisms is a primary concern. However, corticosteroids 
were already shown to be safe in some viral diseases, and 
there is no published evidence indicating the administration 
of corticosteroids causes the viral load to return to peak lev-
els. In addition, no correlation between viral load levels and 
disease severity in patients with viral hemorrhagic fevers 
has been reported. 
Because corticosteroids are not mentioned in the World 
Health Organization guidelines for the management of EVD, 
clinicians can only use them empirically, justifying their use 
based on the immunological basis of the life-threatening 
complications of the illness. The risk/benefit ratio of corti-
costeroids should be determined for each patient. Currently, 
there is no consistent recommendation regarding the type, 
dose and duration of corticosteroids for the treatment of 
EVD. Importantly the effectiveness of corticosteroid treat-
ment may depend critically on the timing of drug admin-
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istration. Immediate treatment following infection might 
help direct the developing immune response towards effec-
tive viral clearance while preventing severe symptoms in 
high-risk patients. Modest immunosuppression by cortico-
steroids might be safe for use in EVD patients as an adjunc-
tive therapy in coordination with intensive supportive  
therapies. 
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